Can Melan-A replace S-100 and HMB-45 in the evaluation of sentinel lymph nodes from patients with malignant melanoma?

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 3, 2006, Pages 324-327

  Kucher, Cynthia ^a   Zhang, Paul J ^a   Acs, Geza ^a   Roberts, Shelley ^a   Xu, Xiaowei ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HMB 42; Lymph nodes; Melan A; Melanoma; S 100

Indexed keywords

MELAN A; PROTEIN S 100;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DISEASE MARKER; FIBROMA; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; MORPHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; STAINING;

ANTIGENS, NEOPLASM; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MART-1 ANTIGEN; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; S100 PROTEINS; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748272691     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/00129039-200609000-00011     Document Type: Article

References (23)

1. Morton DL, Wen DR, Wong JH. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992;127:392-399.
2. Reintgen D, Balch CM, Kirkwood J, et al. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997;225:1-14.
3. Liszkay G, Peley G, Sinkovics I, et al. Clinical significance of sentinel lymph node involvement in malignant melanoma. Pathol Oncol Res. 2003;9:184-187.
4. Davids V, Kidson SH, Hanekom GS. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate. J Clin Pathol Mol Pathol. 2003;56:43-51.
5. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissecting of 1- to 4-mm-thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-266.
6. Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch Dermatol. 1997;133:1014-1020.
7. Piepkorn M, Weinstock MA, Barnhill RL. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Arch Dermatol. 1997;133:995-1002.
8. Staveley OCK, Sotomayor E, Montgomery J, et al. Induction of antigenspecific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA. 1998;95:1178-1183.
9. Cochran AJ, Huang RR, Guo J, et al. Current practice and future directions in pathology and laboratory evaluation of the sentinel node. Ann Surg Oncol. 2001;8(9 Suppl):13S-17S.
10. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma: an immunohistological study. Am J Surg Pathol. 1988;12:612-618.
11. Baisden BL, Askin FB, Lange JR, et al. HMB-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol. 2000;24:1140-1146.
12. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999;86:617-627.
13. Shidham VB, Qi DY, Acker S, et al. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma. Am J Surg Pathol. 2001;25:1039-1046.
14. Messina JL, Glass LF, Cruse CW, et al. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol. 1999;23:686-690.
15. Sheffield MV, Yee H, Dorvault CC, et al. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol. 2002;118:930-936.
16. Xu X, Chu AY, Pasha TL, et al. Immunoprofile of MITF, tyrosinase, Melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol. 2002;26:82-87.
17. Mahmood MN, Lee MW, Linden MD, et al. Diagnostic value of HMB-45 and anti-Melan-A staining of sentinel lymph nodes with isolated positive cells. Mod Pathol. 2002;15:1288-1293.
18. O'Reilly FM, Brat DJ, McAlpine BE, et al. Microphthalmia transcription factor immunohistochemistry: a useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms. J Am Acad Dermatol. 2001;45:414-419.
19. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, Melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740-746.
20. King R, Googe PB, Weilbacher KN, et al. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001;5:51-57.
21. King R, Weilbacher KN, McGill G, et al. Microphthalmia transcription factor: a sensitive and specific melanocytic marker for melanoma diagnosis. Am J Pathol. 1999;155:731-738.
22. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205-211.
23. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T3100 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-Melan-A). J Clin Pathol. 2001;54:196-200.